- $361.79m
- $778.50m
- $512.12m
- 62
- 57
- 95
- 82
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 319 | 340 | 321 | 431 | 512 |
Cost of Revenue | |||||
Gross Profit | 235 | 249 | 234 | 303 | 331 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 294 | 312 | 296 | 421 | 763 |
Operating Profit | 25.5 | 28.2 | 25.4 | 9.9 | -251 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 6.11 | 9.69 | 15.9 | 7.62 | -264 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4.44 | 8.11 | 14.7 | 9.59 | -213 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -12.2 | 6.85 | 16.4 | 19.4 | -159 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18 | -0.659 | 4.38 | 19.4 | -159 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.026 | 0.166 | 0.207 | 1.04 | -0.055 |
Dividends per Share |